THE SEARCH IS ON FOR BETTER WAYS TO PREDICT THE COURSE OF PROSTATE CANCER, ELIZABETH TRACEY REPORTS
Should a man have his early prostate cancer treated or not? That question is the focus of intensive research, with so called ‘tissue markers’ looking likely as candidates to help make this decision. Robert Getzenberg, director of research in the Brady Urological Institute at Johns Hopkins, describes one of the markers his lab is excited about..
GETZENBERG: One of them’s a tissue marker that we’ve found called CRA 61 and it’s found outside the cell in something called the extracellular matrix. Which is the environment outside the cell sort of your lawn outside your house, and that’s very predictive in where the cancer cell goes, whether it stays within the prostate or goes outside the prostate, and we’ve shown that if we control for everything we know today, Gleason score, which is the pathology, PSA, this can add to those values by helping us to figure out who has the kind of disease that may go on to progress versus those who have disease that stays inside the gland. :32
At Johns Hopkins, I’m Elizabeth Tracey.